U.S. & Global Mechanical Heart Valves – Artificial Heart Valve Market (Transcatheter & Surgical) Forecast to 2024
Market Overview
The global artificial heart valve market—encompassing both mechanical and bioprosthetic valves, including surgical and transcatheter variants—is experiencing robust growth, driven by rising incidences of valvular heart diseases, increasing geriatric population, and advancements in minimally invasive cardiac procedures.
The human heart comprises four key valves—the aortic, mitral, pulmonary, and tricuspid—responsible for regulating blood flow across the chambers. Structural defects, either congenital or acquired over time, can lead to conditions such as valvular stenosis and valvular insufficiency, often requiring surgical intervention or replacement.
Mechanical heart valves, designed to mimic the function of natural valves using durable materials like titanium and pyrolytic carbon, offer long-term reliability and are particularly suited for younger patients requiring lifelong solutions. In contrast, transcatheter heart valve replacements (TAVR)—a minimally invasive procedure—are rapidly gaining preference due to shorter recovery times and reduced surgical risk, especially for high-risk and elderly patients.
According to market estimates, the global artificial heart valve market is expected to witness substantial growth through 2024, supported by favourable reimbursement policies, technological advancements, and the rising prevalence of cardiovascular diseases globally.
Market Growth Influencers
Key Drivers
- Rising Prevalence of Valvular Heart Diseases: Approximately 5 million Americans are diagnosed with heart valve disease annually, according to the American Heart Association.
- Aging Population: With age being a major risk factor, the growing geriatric population fuels demand for valve replacement therapies.
- Technological Advancements: Innovations in transcatheter procedures (TAVR/TAVI), improved valve designs, and biocompatible materials are enhancing clinical outcomes.
- Favourable Reimbursement Scenarios: Coverage from agencies such as CMS (U.S.), Central Social Insurance Medical Council (Japan), and European national insurers supports market growth.
Key Restraints
- Stringent Regulatory Pathways: The U.S. FDA’s stringent approval processes delay product launches compared to Europe, impacting market access.
- High Cost of Procedures: Despite clinical benefits, affordability remains a barrier in emerging economies.
- Surgical Risks: Conventional open-heart surgeries pose significant risk for paediatric and elderly patients, although transcatheter options are mitigating this concern.
Market Segmentation
MRFR segments the global artificial heart valve market as follows:
By Valve Type
- Aortic Valve
- Mitral Valve
- Pulmonary Valve
- Tricuspid Valve
By Procedure Type
- Surgical Valve Replacement
- Traditional open-heart surgical approach
- Transcatheter Valve Replacement (TAVR)
- Transfemoral Approach
- Transapical Approach
Regional Analysis
The global market is divided into North America, Europe, Asia-Pacific, and Rest of the World (RoW):
North America
- Largest market driven by high prevalence of cardiovascular diseases and widespread adoption of both surgical and transcatheter valve procedures.
- U.S. leads due to advanced healthcare infrastructure and strong reimbursement systems.
- Canada contributes significantly with increasing adoption of minimally invasive procedures.
Europe
- Second-largest market, with Germany, France, Italy, and the U.K. leading adoption.
- Europe holds the largest share of transcatheter heart valve procedures due to faster regulatory approvals and favorable insurance policies.
- Germany alone accounts for nearly 45.9% of all TAVR procedures in Europe.
Asia-Pacific
- Rapidly growing market driven by rising healthcare awareness, improved access to advanced medical care, and growing elderly populations.
- Japan leads the region, followed by China and India, with increasing adoption of advanced cardiac technologies.
Rest of the World (Middle East, Africa, Latin America)
- Gradual market expansion due to improving healthcare infrastructure and rising incidence of cardiovascular diseases.
- Growth is anticipated in Brazil, Saudi Arabia, and South Africa through 2024.
Prominent Market Players
Key companies operating in the global artificial heart valve market include:
- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic plc
- St. Jude Medical, Inc.
- Edwards Lifesciences Corporation
- Sorin S.p.A.
- Neovasc Inc.
- Colibri Heart Valve, LLC
- On-X Life Technologies Inc.
- Symetis
- Cytograft
- Jenavalve Technology
These companies are focusing on R&D, strategic collaborations, and geographic expansion to strengthen market presence and cater to the rising global demand.
Future Outlook
The global mechanical and artificial heart valve market is poised for strong growth, driven by technological innovation, increasing disease burden, and supportive healthcare policies.
As transcatheter technologies evolve, the market will witness higher adoption rates, especially among high-risk patients. Additionally, continued research into next-generation valve materials, bioengineering, and robot-assisted surgeries will shape the industry’s future.
Emerging markets will play a pivotal role, with growing healthcare investments and awareness accelerating adoption.
Conclusion
The artificial heart valve market stands at the forefront of cardiovascular innovation, offering life-saving solutions to millions worldwide. While regulatory complexities and cost barriers persist, the convergence of clinical innovation, policy support, and rising patient demand ensures a promising growth trajectory through 2024 and beyond.
As healthcare systems globally prioritize minimally invasive treatments and long-term patient outcomes, mechanical and transcatheter heart valves will remain essential components of modern cardiology.